智通财经网·2025-10-16 02:26Core Viewpoint - Rongchang Biologics (09995) shares rose over 5%, reaching a price of HKD 96.45, following the announcement of positive Phase III clinical trial results for Taitasip in treating systemic lupus erythematosus (SLE) published in the New England Journal of Medicine (NEJM) [1] Group 1: Clinical Trial Results - The Phase III trial achieved its primary endpoint, with 67.1% of patients in the Taitasip group showing significant improvement in disease activity, compared to 32.7% in the placebo group [1] - Taitasip is confirmed as a transformative B-cell therapy targeting BLyS/APRIL dual pathways, highlighting its advantages in treating SLE [1] Group 2: Disease Context and Treatment Landscape - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and lead to irreversible damage, with over half of patients experiencing organ damage within 2-6 years of diagnosis [1] - Despite existing treatment options such as corticosteroids, antimalarials, immunosuppressants, and biologics, many patients still face challenges with disease activity, indicating a pressing need for new therapies [1] - Taitasip was approved for SLE treatment in China in March 2021 and was included in the national medical insurance drug list by the end of the same year, marking it as the world's first dual-target biologic new drug for SLE [1]